Stay updated on Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page.

Latest updates to the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedThe page revision has been updated from v3.6.2 to v3.6.3, reflecting a newer version of the page content. The change does not modify displayed study information.SummaryDifference0.0%

- Check18 days agoChange DetectedThe page's revision tag was updated from v3.6.0 to v3.6.2, indicating a minor update to the study documents or page metadata.SummaryDifference0.0%

- Check32 days agoChange DetectedRecruitment status on the study page has been updated to indicate that no participants are being sought. New help/guide sections (How to Read a Study Record, Common Questions, How to Join a Study) were added, and the Intervention/Treatment label was adjusted along with a revision notice (Revision: v3.6.0).SummaryDifference0.4%

- Check39 days agoChange DetectedThe revision label now shows v3.5.5, replacing the previous v3.5.4. This signals that the page has been updated to a newer version.SummaryDifference0.0%

- Check61 days agoChange DetectedThe page's revision label was updated from v3.5.3 to v3.5.4, signaling a new version of the page. This appears to be a minor administrative update rather than a change to the study details or outcomes.SummaryDifference0.1%

- Check82 days agoChange DetectedThe page reflects a minor update to the platform/UI release revision, moving from “Revision: v3.5.2” to “Revision: v3.5.3.” This represents a technical/version change rather than a change to the displayed study information.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page.